Kubota Pharmaceutical Holdings Co., Ltd.

Tokyo Stock Exchange 4596.T

Kubota Pharmaceutical Holdings Co., Ltd. Price to Earnings Ratio (P/E) on January 14, 2025: -1.72

Kubota Pharmaceutical Holdings Co., Ltd. Price to Earnings Ratio (P/E) is -1.72 on January 14, 2025, a 32.77% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.
  • Kubota Pharmaceutical Holdings Co., Ltd. 52-week high Price to Earnings Ratio (P/E) is -1.67 on December 24, 2024, which is 3.38% above the current Price to Earnings Ratio (P/E).
  • Kubota Pharmaceutical Holdings Co., Ltd. 52-week low Price to Earnings Ratio (P/E) is -2.93 on August 01, 2024, which is -69.91% below the current Price to Earnings Ratio (P/E).
  • Kubota Pharmaceutical Holdings Co., Ltd. average Price to Earnings Ratio (P/E) for the last 52 weeks is -2.22.
Key data
Date Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S) Price to Book Ratio (P/B) Dividend Yield
Market news
Tokyo Stock Exchange: 4596.T

Kubota Pharmaceutical Holdings Co., Ltd.

CEO Dr. Ryo Kubota M.D., Ph.D.
IPO Date Dec. 6, 2016
Location Japan
Headquarters 3-7-1 Kasumigaseki
Employees 12
Sector Health Care
Industries
Pharmaceuticals
Description

Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.

StockViz Staff

January 15, 2025

Any question? Send us an email